Kala Pharma Q1 net loss $14.5M; KPI-012 CHASE Phase 2b enrolling with topline data Q1 2024

KALA BIO, Inc.

2023-Q1 EPS reported -$6.99

Q1 2023 net loss $14.5M ($6.99/share) vs $32.9M ($22.18/share) in Q1 2022; no product revenue post-Alcon sale.
Cash and equivalents $63.6M at March 31, 2023; plus $15M CIRM grant awarded April 2023 extends runway into Q1 2025.
KPI-012 for PCED received FDA Fast Track designation; CHASE Phase 2b primary enrollment ongoing; topline data targeted Q1 2024.
Appointed Dr. Francis Mah as Chief Medical Advisor in March 2023 to support clinical development.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

KALA BIO, Inc. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 9, 2023, Kala Pharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2023 and provided a general business update.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

KALA BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-008683

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.